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Abstract
Background The most recent ESC guidelines for percu-
taneous coronary intervention (PCI) recommend the use of
glycoprotein IIb/IIIa inhibitors (GPI) in high risk patients
with non-ST-segment elevation acute coronary syndromes
(NSTE-ACS), particularly in diabetics. Little is known
about the adherence to these guidelines within Europe.
Methods and results Between May 2005 and April 2008
a total of 47,407consecutive patients undergoing PCI were
prospectively enrolled into the PCI-Registry of the Euro
Heart Survey Programme. In the present analysis we
examined the use of GPI in 2,922 diabetics who underwent
PCI for NSTE-ACS. In this high risk population only
22.2% received a GPI; 8.9% upstream and 13.4% during
PCI. The strategy of the individual institution had a major
impact on the usage of GPI. In the multiple regression
analysis clinical instability and complex lesion charac-
teristics were strong independent determinants for the use
of GPI, whereas renal insufﬁciency was negatively asso-
ciated with its use. After adjustment for confounding
variables no signiﬁcant differences in hospital mortality
could be observed between the cohorts, but a signiﬁcantly
higher rate of non-fatal postprocedural myocardial
infarction was observed among patients receiving GPI
upstream.
Conclusions Despite the recommendation for its use in
the current ESC guidelines, only a minority of the diabetics
in Europe undergoing PCI for NSTE-ACS received a GPI.
The use of GPI was mainly triggered by high-risk inter-
ventional scenarios.
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Introduction
Platelet glycoprotein IIb/IIIa inhibitors (GPI) are potent
and rapidly acting anti-platelet agents. They block the ﬁnal
common pathway of platelet aggregation and inhibit the
bridging between activated platelets [1, 2]. Randomized
controlled trials investigating the effect of GPI in patients
with non-ST-segment elevation acute coronary syndromes
(NSTE-ACS) treated with percutaneous coronary inter-
vention (PCI) have revealed a signiﬁcant risk reduction for
death and myocardial infarction at 30 days [3–5]. How-
ever, thienopyridines and stents were not commonly used
in these trials.
Diabetes mellitus is a major risk factor for the devel-
opment of coronary artery disease (CAD), and compared
with their non-diabetic counterparts, diabetic patients have
higher morbidity and mortality in the setting of ST-eleva-
tion myocardial infarction and NSTE-ACS [6, 7]. Rofﬁ
et al. [8] performed a meta-analysis of diabetics enrolled in
large-scale GPI acute coronary syndrome (ACS) trials.
Among diabetic patients the use of GPI was associated
with a signiﬁcant mortality reduction, whereas non-diabetic
patients had no survival beneﬁt. Furthermore, the risk
reduction seemed to be more pronounced in diabetics
treated with PCI.
Consequently, the most recent PCI guidelines of the
ESC recommend GPI in patients with high risk, particu-
larly patients with elevated troponins, ST-depression, or
diabetes and planned or performed PCI [9]. Within the
large Euro Heart Survey (EHS) PCI Registry, which
enrolled consecutive patients from 2005 until 2008, we
evaluated how these guidelines are adhered to in Europe
among diabetics undergoing PCI for NSTE-ACS. In addi-
tion, a multiple logistic regression analysis was conducted
to detect determinants for the use of GPI.
Methods
The PCI-Registry of the EHS Programme
The PCI-Registry is a prospective, multi-centre, observa-
tional study on current practice of unselected patients
undergoing elective or emergency PCI. Consecutive
patients with ACS or stable CAD were recruited within the
period from May 2005 to April 2008. The participating
hospitals were located throughout Europe (176 centres in 33
ESC-countries) and included university hospitals, commu-
nity hospitals, specialist cardiology centres and private
hospitals all performing PCI. The mean annual PCI volume
of the participating facilities was approximately 1,000.
During the speciﬁed period all patients treated with PCI
were prospectively registered and followed during their
clinical course to document patient characteristics, adjunc-
tive medical treatment, procedural details and in-hospital
outcomes.
Study population
In 10,754 patients with NSTE-ACS, diabetic status and
treatment with or without GPI was documented. Among
these patients, 2,922 (27.2%) were diabetics and 7,832
(72.8%) non-diabetics. This present study is a detailed
analysis of the diabetic patients who were divided into
three groups: upstream (treatment started before diagnostic
angiogram), downstream (started during PCI, but not
before PCI) and no GPI.
Data collection
On admission, data on patient characteristics were recor-
ded, including age, gender, cardiovascular risk factors,
concomitant diseases, prior myocardial infarction, prior
stroke, prior cardiovascular interventions and chronic
medical treatment, as well as data on symptoms and pre-
hospital delay. Data on electrocardiographic ﬁndings, bio-
chemical markers, procedural details and adjunctive
therapy were documented. At discharge, major cardiovas-
cular, cerebrovascular adverse events, puncture site com-
plications and recommended medical treatment were
recorded.
Every participating centre was committed to include
every consecutive patient undergoing PCI during selected
time periods. If continuous enrollment was not feasible due
to high annual numbers of PCI, these centres were asked to
recruit consecutive patients from day 1 to 7 of every cal-
endar month during the entire study period. All patients
gave written informed consent for processing their anon-
ymous data. Electronic case report forms were used for
data entry and transferred via the web to a central database
located in the European Heart House, where they were
edited for missing data, inconsistencies and outliers.
Additional editing of the data as well as the statistical
analyses for this publication was performed at the Institut
fuer Herzinfarktforschung Ludwigshafen an der Universi-
taet Heidelberg, Germany. The study was approved by the
ethics committees responsible for the participating centres
as required by local rules.
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123Deﬁnitions
In patients without initial myocardial infarction, clinical
signs of ischemia and relevant increases of cardiac bio-
markers were deﬁned as postprocedural myocardial
infarction. Postprocedural reinfarction was diagnosed if
patients had signs of recurrent ischemia and an additional
relevant increase of cardiac biomarkers. Bleeding compli-
cations were classiﬁed as major when the patient had an
intracranial bleed or overt clinical bleeding with a drop in
hemoglobin of greater than 5 g/dl. Chronic renal failure
was diagnosed by any of the following: serum creatinine
[2 mg/dl or 200 lmol/l in the past, on dialysis or history
of renal transplantation. Major adverse cardiac events
(MACE) comprise all deaths and post-procedural myo-
cardial infarctions during hospital stay.
Statistical methods
Categorical data are presented as absolute numbers and
percentages, metrical data as medians with 25th and 75th
percentiles. The frequencies of categorical variables in two
populations were compared between two groups by Pearson
v
2 test and by calculating odds-ratios (OR) and 95% conﬁ-
dence intervals (CI). Continuous and ordinal variables were
compared by Mann–Whitney–Wilcoxon test. Descriptive
statistics were calculated from the available cases.
The impact of different baseline, angiographic and
procedural variables on the use of upstream and down-
stream GPI treatment was evaluated by marginal logistic
regression models and calculating the odds ratios with 95%
conﬁdence intervals using generalized equations with
exchangeable working correlation matrix in order to
account for clustering by centres. The multivariate analysis
regarding the upstream use compared patients receiving
GPI before PCI with those treated never or later and
included as explanatory variables: age (per 10-year
increase), female gender, peripheral vascular disease
(PAD), chronic renal failure, non-ST elevation myocardial
infarction (NSTEMI), hemodynamic instability on admis-
sion (cardiogenic shock or/and resuscitation), chronic
medication with acetylsalicylic acid (ASA) and vitamin K
antagonist, usage of unfractionated (UFH) or low mole-
cular weight heparin (LMWH) before or during PCI.
Concerning the downstream regime the groups receiving
GPI during PCI versus no GPI were compared excluding
patients on upstream treatment and the following variables
were incorporated in the analysis: age (per 10-year
increase), chronic renal failure, Western Europe, Mediter-
ranean region, radial access, [1 segment treated, type C
lesion, drug-eluting stents (DES), no/slow ﬂow during
intervention, acute segment occlusion. These variables
were speciﬁed by clinical considerations and all of them
had a bi-variate association with hospital mortality with
p\0.2. Furthermore, we evaluated the effect of upstream
and downstream GPI treatment on hospital mortality and
non-fatal myocardial infarction. Odds ratios for death
versus no MACE and non-fatal myocardial infarction
versus no MACE were estimated in multinomial logit-
regression models with adjustment for age (per 10-year
increase), hemodynamic instability, acute NSTEMI, three-
vessel disease, history of chronic renal failure, prior stroke
and PAD, downstream treatment also for multi-segment
PCI, acute segment occlusion and no/slow ﬂow. The no
GPI group with the lowest risk for death and myocardial
infarction was deﬁned as reference group.
P values B0.05 were considered signiﬁcant. All p values
are results of two-tailed tests and are not adjusted for
multiple testing. The analysis was performed with the
SAS
 system release 9.1 on a personal computer (SAS
Institute, Inc., Cary, NC, USA).
Results
Patients and baseline characteristics
For the present analysis 2,922 diabetic patients with NSTE-
ACS were examined and stratiﬁed into three categories:
259 patients (8.9%) receiving upstream, 391 patients
(13.4%) downstream and 2,272 patients (77.8%) no GPI.
Non-diabetics were more frequently treated with GPI. In
comparison to diabetics the percentage of upstream
(12.0%) and downstream (14.9%) treatment was signiﬁ-
cantly higher (p\0.0001). The baseline characteristics of
the diabetics patients are shown in Table 1. There was no
relevant age difference between the three groups. Women
more often received upstream treatment. GPI was less
commonly administrated to patients with a history of PAD
and chronic renal failure.
GPI in different European regions
The percentage of diabetic patients receiving upstream
treatment was similar across Europe, but downstream
treatment was most frequent in Mediterranean countries
followed by Central and Western Europe. The numbers of
patients from Northern Europe which contributed data are
too small to be representative (Fig. 1). Large differences in
the utilization of GPI were observed between the partici-
pating centres (Fig. 2).
Initial assessment and diagnosis
The majority of diabetics presenting with NSTEMI or
cardiogenic shock did not receive a GPI, but in those who
Clin Res Cardiol (2010) 99:375–383 377
123did, it was given rather upstream than downstream
(Table 2).
Angiographic and interventional characteristics
Diabetic patients undergoing PCI of left main stem (LM),
bypass grafts and more than one segment more frequently
received GPI. Nevertheless, only 34.6% of patients with
PCI of LM, 34.8% with bypass interventions and 30.9%
with multi-segment PCI were treated with GPI. Lesion
characteristics were more complex among patients with
downstream treatment.
The stenting rate was higher among patients with
GPI. Diabetic patients with DES more often received
downstream treatment. There were no major differences in
procedural success among the groups. Downstream
administration of GPI was more commonly observed in
patients with acute segment closure and no/slow ﬂow
(Table 3).
Antithrombotic medication
Diabetics with chronic ASA medication were less fre-
quently treated with GPI. Before and during PCI diabetics
with GPI were more likely to receive ASA and LMWH,
and less likely to receive UFH. There were no relevant
differences in the rate of clopidogrel loading doses
(upstream and started in the catheterization laboratory)
Table 1 Baseline characteristics
No GPI
N = 2,272
Upstream
N = 259
P value
(no vs. up)
Downstream
N = 391
P value
(no vs. down)
Demographics
Age (years) 67.6 (59.6–74.9) 68.6 (60.4–75.5) ns 66.9 (59.8–73.4) ns
Women 788 (34.7%) 110 (42.5%) \0.05 136 (34.8%) ns
BMI (kg/m
2) 28.4 (25.9–31.3) 28.7 (25.8–32.9) ns 28.1 (25.8–31.4) ns
History relevant to CAD
Prior myocardial infarction 833/2,257 (36.9%) 93/249 (37.3%) ns 143/383 (37.3%) ns
Prior PCI 641/2,256 (28.4%) 54/249 (21.7%) \0.05 103/383 (26.9%) ns
Prior CABG 219/2,256 (9.7%) 23/249 (9.2%) ns 46/383 (12.0%) ns
Hx of stroke 176/2,256 (7.8%) 18/249 (7.2%) ns 19/383 (5.0%) B0.05
Hx of peripheral vascular disease 278/2,256 (12.3%) 16/249 (6.4%) \0.01 34/383 (8.9%) 0.05
Hx of chronic renal failure 217/2,256 (9.6%) 16/249 (6.4%) ns 21/383 (5.5%) \0.01
Risk factors
Hypertension 1,880/2,263 (83.1%) 216/257 (84.0%) ns 321/389 (82.5%) ns
HLP 1,519/2,166 (70.1%) 194/246 (78.9%) \0.01 275/380 (72.4%) ns
Current/former smoker 1,003/2,185 (45.9%) 101/249 (40.6%) ns 176/376 (46.8%) ns
Region
Western Central Mediterranean Northern
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Fig. 1 Use of GP IIb/IIIa inhibitors in different European regions
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Fig. 2 Use of GP IIb/IIIa inhibitors per centre
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123between the three groups. The rate of 300 and 600 mg
doses were also similar (data not shown). Patients treated
with upstream GPI more frequently received clopidogrel at
discharge (Table 4).
Distribution of the different GPI
In an upstream treatment regime tiroﬁban (n = 180,
69.5%) was most often used, followed by eptiﬁbatide
(n = 60, 23.2%) and abciximab (n = 23, 8.9%).
Downstream the use of abciximab (n = 151, 38.6%)
increased, the use of tiroﬁban (n = 147, 37.6%) decreased,
whereas the percentage of eptiﬁbatide did not change
(n = 93, 23.8%).
Determinants for the upstream use of GPI
After adjustment for confounding variables NSTEMI was
an independent determinant for the upstream use of GPI in
diabetics. There was a strong tendency towards a higher
Table 2 Initial assessment and diagnosis
No GPI
N = 2,272
Upstream
N = 259
P value
(no vs. up)
Downstream
N = 391
P value
(no vs. down)
Diagnosis
NSTEMI 930 (40.9%) 171 (66.0%) \0.0001 176 (45.0%) ns
Unstable angina 1342 (59.1%) 88 (34.0%) \0.0001 215 (55.0%) ns
Cardiogenic shock 26/2,269 (1.1%) 13 (5.0%) \0.0001 8/390 (2.1%) ns
Resuscitation 22/2,270 (1.0%) 8 (3.1%) \0.01 4/390 (1.0%) ns
Left ventricular function
Reduced (\50%) 740/1,897 (39.0%) 79/196 (40.3%) ns 114/304 (37.5%) ns
Table 3 Angiographic and interventional characteristics
No GPI
N = 2,272
Upstream
N = 259
P value
(no vs. up)
Downstream
N = 391
P value
(no vs. down)
Stenosed vessels (C50%)
Left main stem 112 (4.9%) 13 (5.0%) ns 25 (6.4%) ns
Multi-vessel disease 1,559 (68.6%) 158 (61.0%) \0.05 279 (71.4%) ns
Arterial access
Femoral 2,008/2,271 (88.4%) 223/258 (86.4%) ns 332 (84.9%) B0.05
Radial 244/2,271 (10.7%) 34/258 (13.2%) ns 58 (14.8%) \0.05
Treated vessels
Left main stem 51 (2.2%) 10 (3.9%) ns 17 (4.3%) B0.05
Bypass 60 (2.6%) 13 (5.0%) \0.05 19 (4.9%) \0.05
[1 segment 701 (30.9%) 105 (40.6%) ns 209 (53.5%) \0.0001
Lesion characteristics
Type C 701/2,272 (30.7%) 88/257 (34.2%) ns 164/390 (42.1%) \0.0001
Bifurcation 412/2,266 (18.2%) 50/258 (19.4%) ns 96/390 (24.6%) \0.01
TIMI ﬂow 0–2 before PCI 897/2,248 (39.9%) 149/258 (57.8%) \0.0001 187/390 (47.9%) \0.01
Therapeutic devices
Stent implantation 2,078 (91.5%) 246 (95.0%) 0.05 373 (95.4%) \0.01
Bare-metal stent 1,201/2,271 (52.9%) 134 (51.7%) ns 152 (38.9%) \0.0001
Drug-eluting stent 970/2,271 (42.7%) 135 (52.1%) \0.01 261 (66.8%) \0.0001
Balloon pump 19/2,237 (0.8%) 10/258 (3.9%) \0.0001 7/384 (1.8%) ns
Procedural details
TIMI 3 ﬂow after PCI 2,090/2,262 (92.4%) 241/258 (93.4%) ns 358 (91.6%) ns
\50% Stenosis after PCI 2,129/2,265 (94.0%) 246 (95.0%) ns 377/390 (96.7%) \0.05
Acute segment closure 15/2,225 (0.7%) 3/253 (1.2%) ns 10/379 (2.6%) \0.001
No/slow ﬂow 26/2,224 (1.2%) 3/253 (1.2%) ns 21/379 (5.5%) \0.0001
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123utilization among patients with hemodynamic instability
(cardiogenic shock or/and resuscitation). Upstream GPI
was more often accompanied by the use of LMWH than
UFH (Fig. 3).
Determinants for the downstream use of GPI
The multivariate analysis revealed the following indepen-
dent determinants for the downstream use of GPI in
decreasing order of importance (using odd ratios): Medi-
terranean region, no/slow ﬂow, [1 segment treated, DES
and type C lesion. Patients with acute segment occlusion
tended to be more often treated with GPI, but the level of
signiﬁcancy was just missed. Renal insufﬁciency was
negatively associated with downstream use (Fig. 4).
Hospital complications
In comparison to diabetics with no GPI therapy the inci-
dence of hospital death was signiﬁcantly higher in patients
with upstream (4.6 vs. 1.7%, p = 0.001) and similar in
patients with downstream (1.8 vs. 1.7%, p = 0.97) treat-
ment (Fig. 5). After adjustment for confounding variables
no signiﬁcant differences in the risk for hospital death
could be seen in the upstream (OR 1.54, 95% CI 0.67–
3.57) and downstream (OR 0.81, 95% CI 0.31–2.11) versus
the no GPI group.
Compared to diabetics without GPI the incidence of
non-fatal postprocedural myocardial infarction (8.1 vs.
1.1%, p\0.0001) and major bleedings (3.1 vs. 1.0%,
p = 0.008) occurred more often among those treated with
an upstream regime. In patients with downstream regime
the rate of postprocedural myocardial infarction (3.6 vs.
1.1%, p = 0.0001) and bleedings (2.6 vs. 1.0%, p = 0.02)
was also increased. In the multiple regression analysis
diabetics with upstream treatment (OR 4.12, 95% CI 2.01–
8.48) remained at elevated risk for myocardial infarction
post PCI. There was also a tendency towards an increased
risk for postprocedural myocardial infarction in the
downstream group (OR 1.95, 95% CI 0.85–4.46). No
Table 4 Antithrombotic medication
No GPI
N = 2,272
Upstream
N = 259
P value
(no vs. up)
Downstream
N = 391
P value
(no vs. down)
On admission
ASA 1,706/2,173 (78.5%) 166/234 (70.9%) \0.01 272/370 (73.5%) \0.05
Clopidogrel 760/2,171 (35.0%) 86/235 (36.6%) ns 104/369 (28.2%) \0.05
Ticlopidine 67/2,171 (3.1%) 3/235 (1.3%) ns 18/369 (4.9%) ns
Vitamin K antagonist 69/2,171 (3.2%) 6/234 (2.6%) ns 8/369 (2.2%) ns
Before or during PCI
ASA 1,726/2,267 (76.1%) 216/257 (84.0%) \0.01 342/390 (87.7%) \0.0001
Clopidogrel overall 1,806/2,267 (79.7%) 217 (83.8%) ns 304 (77.7%) ns
Clopidogrel loading dose upstream 1,142/2,236 (51.1%) 138/254 (54.3%) ns 183/377 (48.5%) ns
Clopidogrel loading dose started in cathlab 690/2,268 (30.4%) 72/258 (27.9%) ns 103/390 (26.4%) ns
Ticlopidine 78/2,267 (3.4%) 6 (2.3%) ns 21 (5.4%) ns
Unfractionated heparin 2,035/2,271 (89.6%) 169 (65.3%) \0.0001 333 (85.2%) 0.01
Low molecular weight heparin 763/2,270 (33.6%) 156 (60.2%) \0.0001 180 (46.0%) \0.0001
At discharge
ASA 2,128/2,186 (97.3%) 235/242 (97.1%) ns 367/381 (96.3%) ns
Clopidogrel 1,980/2,185 (90.6%) 232/242 (95.9%) \0.01 341/381 (89.5%) ns
Ticlopidine 101/2,185 (4.6%) 6/242 (2.5%) ns 22/381 (5.8%) ns
Vitamin K antagonist 61/2,180 (2.8%) 5/241 (2.1%) ns 6/379 (1.6%) ns
GPI less likely GPI more likely
0 0,5 1 1,5 2 2,5 3 3,5 4
LMWH
UFH
Vit K antagonist
ASA
NSTEMI
PAD
Female gender
Age
Shock/CPR
Fig. 3 Independent determinants for the upstream use of GP IIb/IIIa
inhibitors
380 Clin Res Cardiol (2010) 99:375–383
123signiﬁcant difference in the occurrence of non-fatal strokes
was observed (Fig. 5).
Discussion
This subgroup analysis of the EHS PCI Registry with
nearly 3,000 diabetics undergoing PCI for NSTE-ACS
investigated the use of GPI in clinical practice. The registry
identiﬁed a low use of GPI despite the recommendation for
its application in the current ESC guidelines. In particular,
clinical stable diabetics with chronic renal insufﬁciency
were less frequently treated. Patients with NSTEMI and
hemodynamic instability were more likely to receive
upstream, and those with more complex lesions down-
stream administration of GPI. After adjustment for con-
founding factors no signiﬁcant differences in hospital
mortality could be observed.
Rofﬁ and colleagues demonstrated that there is a clear
beneﬁt of GPI among diabetics with NSTE-ACS. There is a
pathophysiological plausibility to support this ﬁnding.
Diabetics with ACS are at higher risk for major adverse
events than non-diabetic patients. It has been hypothesized
that hemostatic factors play an important role; altered
platelet activation as well as impaired ﬁbrinolysis have
been found in diabetics [10, 11].
The most recent ESC guidelines for PCI and NSTE-
ACS recommend the use of GPI in high risk patients with
ACS, particularly in patients with diabetes undergoing PCI
[9, 12]. In previous observational studies a low use of GPI
has already been documented [13]. In the 2005 Euro Heart
Survey on coronary revascularization, which analyzed data
from 2000/2001 only 32% of the patients undergoing PCI
for NSTE-ACS received GPI [14]. However, no difference
was seen between patients with and without diabetes,
which is in contrast to contemporary practice. In the EHS
PCI Registry, diabetics with NSTE-ACS were less likely to
receive GPI compared to their non-diabetic counterparts. In
the USA, the use of GPI appears to be higher [15]. Results
from the CRUSADE Quality Improvement Initiative
revealed the use of GPI in over 50% of the patients with
NSTE-ACS undergoing coronary angiography within 48 h
of presentation.
A multiple logistic regression analysis was performed to
identify the reasons for and against GPI treatment in clin-
ical practice. Clinical status had a major impact on the
decision of the treating physician to use GPI upstream.
Diabetics with hemodynamic instability, and NSTEMI
were more likely to receive GPI upstream than down-
stream, however, the majority of patients with elevated
troponins, cardiogenic shock and resuscitation did not
actually receive GPI. On the contrary, chronic renal
insufﬁciency made it less probable for the patient to be
treated with GPI. It is well known that the use of GPI is
associated with an increased risk for bleeding complica-
tions in patients with impaired renal function [16], how-
ever, the incidence of bleeding events can be minimized by
weight-based heparin dosing, reduction of the GPI dose
and early vascular access sheath removal following PCI
[17–19]. In the end, the net clinical beneﬁt might even be
greater in patients with renal insufﬁciency despite the
bleeding risk [20].
As expected, angiographic and procedural factors
strongly inﬂuenced the downstream application of GPI.
Diabetics undergoing complex interventions were more
likely to receive GPI. Peri-procedural complications such
as no/slow ﬂow, and acute segment occlusion were inde-
pendent predictors for administration of downstream GPI.
Patients receiving DES were also more frequently treated
with a downstream regime.
Furthermore, the strategy of the individual institution
was one of the most meaningful determinants for the use of
GPI, with large differences observed in the utilization of
GPI between the participating centres. In some centres all
patients, in others no patients received GPI. This is in line
with ﬁndings from the Euro Heart Survey on coronary
012345678
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123revascularization [14]. Large regional differences were also
seen in our analysis; with the usage of GPI, in particular
downstream, highest in Mediterranean countries.
Patients receiving GPI constitute a high risk group
among diabetics with NSTE-ACS, and their risk for hos-
pital death, postprocedural myocardial infarction and major
bleeding is accordingly increased. This is mainly due to a
strong selection bias for the use of GPI in patients with
unstable presentation, and those undergoing complicated
intervention. In the multiple regression analysis no signif-
icant differences in hospital mortality could be observed
among the three patient cohorts. However, even after
adjustment for confounding variables the risk for myocar-
dial infarction post PCI is increased among patients
receiving GPI, in particular in those with upstream treat-
ment. This observation is in contrast to previous random-
ized controlled and observational studies favouring GPI [8,
21]. One possible explanation is the fact that GPI were
more frequently used in high-risk scenarios and it may
remain a substantial selection bias, which cannot be covered
by the routine parameters in the multivariate analysis.
Despite the low use in clinical practice there is an
ongoing debate about the proper role of GPI in the man-
agement of patients with NSTE-ACS today. As mentioned
earlier dual antiplatelet therapy and stents were not rou-
tinely used at the time studies supporting the GPI use were
performed. Studies with patients undergoing elective PCI
after pretreatment with clopidogrel demonstrated little or
no beneﬁt of GPI [22, 23]. New studies published after the
ﬁnalization of the ESC PCI guidelines have provided
additional conﬂicting data about the routine use of GPI in
patients undergoing PCI for NSTE-ACS, particulary in the
light of new antithrombotic treatment strategies.
IntheISAR-REACT2trialabciximabindeedreducedthe
risk of adverse events in patients with NSTE-ACS under-
going PCI notwithstanding clopidogrel pre-treatment and
high stenting rate [24]. However, considering that prasugrel
mightbeastrongerandmorestableantiplateletagenttherole
of GPI use in the setting of ACS will possibly be redeﬁned
[25]. In the ACUITY trial bivalirudin alone was associated
withsimilarratesofischemiaandsigniﬁcantlylowerratesof
bleedingincomparisontoGPIplusheparin[26].Inaddition,
the optimal timing for the initiation of treatment with GPI in
patients with ACS is still unclear. In the recently published
EARLY ACS trial the early use was not superior to the
provisional use of eptiﬁbatide after coronary angiography in
patients with NSTE-ACS [27].
Limitations
As the nature of the study is exploratory, the ﬁndings
should be interpreted cautiously. As stated above,
individual interpretation of the clinical setting by the
treating physicians cannot be reﬂected by the data collected
in registries and therefore might contribute to a remaining
selection bias which cannot adjust for even in thoughtful
multivariate analysis.
Summary
In this analysis of the PCI-Registry of the Euro Heart
Survey Programme a low use of GPI was identiﬁed among
diabetics undergoing PCI for NSTE-ACS. The strategy of
the individual institution was one of the most powerful
determinants for the use of GPI. Patients were also more
likely to receive GPI in a high risk scenario. Clinical
instability was a strong determinant for an upstream, and
complex lesions and interventions for a downstream
application of GPI. Chronic renal failure was negatively
associated with the use of GPI. After adjustment for con-
founding variables no signiﬁcant differences in hospital
mortality could be observed between the three groups, but
a signiﬁcantly higher rate of non-fatal myocardial infarc-
tion was seen post PCI among patients receiving GPI
upstream. However, it may remain a substantial selection
bias, which cannot be fully eliminated even by using a
multivariate analysis.
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Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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